TCGA-60-2703-01A-11R-2045-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- ANGIOGENESIS+0.520
- G2M_CHECKPOINT+0.500
- UV_RESPONSE_DN+0.450
- MYC_TARGETS_V1+0.440
- MITOTIC_SPINDLE+0.430
- ANDROGEN_RESPONSE+0.380
- MYC_TARGETS_V2+0.360
- WNT_BETA_CATENIN_SIGNALING+0.360
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- ALLOGRAFT_REJECTION-0.300
- XENOBIOTIC_METABOLISM-0.240
- PEROXISOME-0.210
- UV_RESPONSE_UP-0.190
- BILE_ACID_METABOLISM-0.180
- ESTROGEN_RESPONSE_EARLY-0.170
- ESTROGEN_RESPONSE_LATE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598197 | fetal | fetal | 0.878 |
| 2 | ERR2598184 | fetal | fetal | 0.860 |
| 3 | 20110025.TNBC | — | E | 0.853 |
| 4 | MNG2 | — | — | 0.843 |
| 5 | TCGA-22-4593-01A-21R-1820-07 | — | cohortSQ1 | 0.833 |
| 6 | SRR8942947 | — | — | 0.831 |
| 7 | ERR2598180 | fetal | fetal | 0.822 |
| 8 | MDT-AP-3334 | Med | Medulloblastoma | 0.821 |
| 9 | TCGA-21-5783-01A-41R-2187-07 | — | cohortMD1 | 0.821 |
| 10 | ERR2598185 | fetal | fetal | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.520 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |